MINACID

Nalidixic Acid Tablets BP

500 mg

Composition: Each uncoated tablet contains:
Nalidixic Acid BP 500 mg
Excipients q.s.

THERAPEUTIC INDICATIONS:
Nalidixic acid is recommended for the treatment of acute or chronic infections—particularly of the urinary tract—caused by Gram-negative organisms (other than *Pseudomonas* species) that are susceptible to nalidixic acid. It may also be used to treat selected cases of Gram-negative gastrointestinal infections caused by organisms susceptible to nalidixic acid.

DOSAGE AND ADMINISTRATION
Oral route.
As directed by the physician.
Adults (including the elderly): for acute infections, 1 g four times daily for at least seven days, reducing to 0.5 g four times daily for chronic infections.

CONTRAINDICATIONS:
Nalidixic acid is contraindicated in infants under 3 months of age and in patients with a history of seizure disorders, porphyria, or hypersensitivity to nalidixic acid or related compounds.

WARNINGS AND PRECAUTIONS FOR USE:
Nalidixic acid may precipitate a hemolytic reaction in individuals with glucose-6-phosphate dehydrogenase deficiency. Prescribe with caution in patients with hepatic impairment, moderate renal impairment, or severe cerebral arteriosclerosis. Monitor complete blood count, renal function, and hepatic function during long-term therapy (more than 2 weeks). Special care should be taken when treating patients with renal impairment. Patients should avoid excessive exposure to sunlight. Discontinue treatment if symptoms of neuropathy or arthropathy occur. Discontinue treatment if patients experience tendon pain, inflammation, or tendon rupture.

DRUG INTERACTIONS
- Anticoagulants (coumarins or indandione derivatives): Due to competition for binding sites between nalidixic acid and anticoagulants. It may be necessary to reduce the anticoagulant dosage and monitor prothrombin time until a satisfactory ratio is achieved.
- Probenecid: Associated with reduced efficacy against urinary pathogens and an increased incidence of side effects.
- NSAIDs: increased likelihood of seizures reported.
- Melphalan: high toxicity reported.
- Cyclosporine: increased nephrotoxicity may occur.
- Other antibacterials: chloramphenicol, nitrofurantoin, and tetracycline may inhibit the action of nalidixic acid.
- Estrogens: theoretical risk of contraceptive failure with estrogen-containing preparations.
- Oral typhoid vaccine: live vaccines may be inactivated by antibiotics.
- Strontium ranelate, sucralfate, and products containing divalent or trivalent cations—such as iron, aluminum, zinc, magnesium, and calcium—may inhibit the absorption of nalidixic acid.

ADVERSE EFFECTS
Blood disorders have been reported, including eosinophilia, leukopenia, thrombocytopenia, hemolytic anemia, and thrombotic events.
Metabolic acidosis has been reported.
Gastrointestinal effects have been reported, including nausea, diarrhea, abdominal pain, and cholestasis.

Cutaneous reactions have been reported, including allergic reactions (urticaria and pruritus) and photosensitivity reactions (erythema, bullous eruptions). Other reported cutaneous reactions include Stevens-Johnson syndrome, erythema multiforme, eosinophilia, angioedema, and anaphylaxis. Headache, dizziness, vertigo, sleep disturbances, depression, hallucinations, drowsiness, confusion, agitation, and taste and smell disturbances have been reported. Psychosis and toxic convulsions—sometimes associated with overdose—have been reported. Patients with a history of seizures or cerebral arteriosclerosis are at higher risk of seizures when taking nalidixic acid.

PREGNANCY AND BREASTFEEDING
Although there is no evidence that nalidixic acid has any harmful effects during pregnancy, its use during the first trimester should be carefully considered. When treating breastfeeding women, the fact that traces of nalidixic acid are excreted in breast milk should be taken into account.

OVERDOSE
In the event of an emergency, it is recommended that the stomach be emptied and symptomatic treatment administered as necessary.

Storage: Store below 30°C in a cool, dry place.
Protect from light.

Keep medicines out of the reach of children.

Presentation: Blister pack of 10 tablets.

Manufactured by:
US Pharma®
(INDIA) Private Limited
Pioneering Excellence. Redefining Quality.
www.uspharma.in